Navigation Links
CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone

614-3472

(international) five minutes prior to the start time and provide the passcode 77712259. A replay of the call will be available from 7:30 p.m. ET on March 26, 2007 until April 9, 2007. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international), and provide the passcode 59287638. A live audio webcast of the call will also be available on the "Investors" section of the company's website. An archived webcast will be available on the CombinatoRx website, www.combinatorx.com, approximately two hours after the event and will be archived for 14 days.

About CRx-102

CRx-102 is an oral synergistic combination drug candidate containing the cardiovascular agent dipyridamole and an unconventionally low dose of the glucocorticoid steroid prednisolone. CRx-102 works through a novel mechanism of action in which dipyridamole selectively amplifies prednisolone's anti-inflammatory and immuno-modulatory activities without replicating its side effects. In phase 2 clinical trials, CRx-102 demonstrated a powerful anti-inflammatory effect and rapid onset of action in patients with osteoarthritis and rheumatoid arthritis, as well as in a biomarker study, and was generally well tolerated. CRx-102 is being developed in a modified-release commercial formulation for the treatment of multiple immuno-inflammatory diseases.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology wh
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
2. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
3. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
4. CombinatoRx to Present Combination High Throughput Screening (cHTS) Data at Upcoming AACR Meeting
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. XTL Provides Update on Phase I Clinical Trial of XTL-2125
7. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
8. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
11. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
Post Your Comments:
(Date:9/18/2014)... ARBOR, Mich. , Sept. 18, 2014  A ... Research will allow the University of Michigan to establish ... The Glenn Center for Aging Research at ... evidence that drugs can slow the effects of aging ... unlock mechanisms of aging that can help develop medications ...
(Date:9/18/2014)...  Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment ... the Company,s Board of Directors, effective September 12, 2014. ... the Board of seven members. Dr. Altstiel will also ... and a member of the Audit and Compensation Committees ... Scientific Advisory Board, a position he has held since ...
(Date:9/18/2014)... Sept. 18, 2014  Spring Bank Pharmaceuticals, Inc., ... the treatment of RNA viruses, today announced a ... (NIH) for animal testing of the Company,s lead ... as "Special Pathogens," against which currently there are ... Spring Bank,s proprietary Small Molecule Nucleic ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... 2011 UCB, a leading biopharmaceutical company at the forefront ... College of Gastroenterology (ACG) meeting in Washington, D.C. by reinforcing ... disease. At this year,s ACG meeting, a large body of ... in treatment of moderate to severe Crohn,s disease. ...
... Natrix Separations, Inc. announced today new members of its leadership ... Officer and Molly S. McGlaughlin as Vice President of Business ... of Directors since mid-2010, and will continue to hold a ... C. Howie Honeyman, Ph.D. will continue as Senior Vice ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 2UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 3Natrix Separations Introduces New Leadership Team 2Natrix Separations Introduces New Leadership Team 3
(Date:9/18/2014)... Wis. (PRWEB) September 18, 2014 It is ... engage in health and wellness. Once again, Evensong Spa ... Spa Week by offering three services at a special $50 ... Spa, managed by Marcus Hotels & Resorts , is ... national event encouraging Americans to embrace health and wellness by ...
(Date:9/18/2014)... exercise is good for you. But new research from ... an added benefit for cancer patients undergoing chemotherapy. , ... found that combining exercise with chemotherapy shrunk tumors more ... professor in the School of Nursing and director of ... the senior author on the study, which appears in ...
(Date:9/18/2014)... Salt Lake City, UT (PRWEB) September 18, 2014 ... across North America will be recognizing their shared fundraising ... on Thursday, Sept. 25. , The first-ever Dance ... of more than $20 million projected to be raised ... at their community’s CMN Hospital. Donations generated through Dance ...
(Date:9/18/2014)... -- don,t worry, it,s a good thing! As scientists ... are bad. Many active enzymes and bacteria are merely ... an important part of our digestive system or can ... , an opportunistic yeast pathogen and model organism for ... personal ecosystem. However, when our immune system is stressed ...
(Date:9/18/2014)... ANGELES (September 18, 2014) The National Institutes ... funding from a four-year, $1.3 million grant to the ... in the research and development of a vaccine to ... and Methicillin-resistant Staphylococcus aureus (MRSA). , ... of the NIH awarded the grant to LA BioMed ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... MOUNTAIN VIEW, Calif., April 25 MAP,Pharmaceuticals, Inc. (Nasdaq: ... following upcoming investor conferences on April 30th and,May 6th, 2008:, ... Wednesday, April 30, 2008 9:10 am, Eastern Time, ... Tuesday, May 6, 2008 10:10 am, Eastern Time ...
... N.C., April 25 Managing multi-generational,diversity is emerging ... study with 23 leading companies, 80 percent deem ... yet only one-third say,their companies offer training in ... download an excerpt of,this new research, The High-Performing ...
... Malaria,Day, the American Red Cross is joining with its ... to this deadly disease., Each year, malaria, a ... mostly children in Africa. More,than 1 million people die ... the American Red Cross and its partners in the ...
... Leaders for ... World Malaria Day, World ... Bill, WASHINGTON, April 25 A volunteer nurse from,Zambia and ... to emphasize the importance of joint efforts in the,fight against malaria ...
... cancers that depend on hormones and those that ... 25th in the open-access journal PLoS Genetics. , ... which usually require treatment with surgery and anti-hormone ... hormone independent breast cancers, which are treated with ...
... THURSDAY, April 24 (HealthDay News) -- Women who play sports ... thighbone to the shinbone. Beyond the immediate pain and swelling ... type of injury may lead to another vexing health problem. ... found that young women who had surgery to repair the ...
Cached Medicine News:Health News:MAP Pharmaceuticals to Present at Upcoming Investor Conferences 2Health News:Multi-generational Diversity Top Challenge for Businesses Today: Leading Company to Share Insights June 4-6 2Health News:Uniting to Fight Malaria Around the World 2Health News:Uniting to Fight Malaria Around the World 3Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 2Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 3Health News:Women Risk Bone Loss After Knee Surgery 2Health News:Women Risk Bone Loss After Knee Surgery 3
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Duckbill type sharp. 3 mm wide x 8 mm long curved blade. Octagonal handle....
9 mm slightly curved blade. Hexagonal handle....
Medicine Products: